Yahoo · Sep 11, 2026
Biohaven’s epilepsy drug hit with FDA clinical hold
Pivotal study enrolment has been paused while Biohaven characterises a metabolite of opakalim and its safety in humans.
NYSE · BHVN
Biohaven Ltd.
Healthcare · Biotechnology
$12.34
Down-$0.27 (-2.15%)
Updated Sep 16, 2026, 5:07 PM
SID Score
4.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.21B
- P/E ratio
- -1.55
- Dividend yield
- 0.00%
- 52-week range
- $8.03 – $18.24
- Volume
- 3.08M
- Avg. volume
- 3.75M
Price performance
BHVN price history
1M range · 20 trading sessions · Daily adjusted prices
BHVN closed at $12.34 after 20 trading sessions, down 9.06% for the selected period.
- Last close
- $12.34
- Period change
- -9.06%
- Period low
- $12.34
- Period high
- $16.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $12.57 | $12.67 | $11.96 | $12.34 | 3.08M |
| Sep 14, 2026 | $12.52 | $12.87 | $12.52 | $12.64 | 1.65M |
| Sep 11, 2026 | $13.03 | $13.37 | $12.58 | $12.71 | 2.86M |
| Sep 10, 2026 | $13.525 | $13.84 | $12.435 | $12.79 | 8.32M |
| Sep 9, 2026 | $14.62 | $15.46 | $14.415 | $15.00 | 2.82M |
| Sep 8, 2026 | $14.91 | $15.80 | $14.33 | $14.72 | 3.31M |
| Sep 4, 2026 | $15.52 | $15.805 | $15.21 | $15.69 | 1.9M |
| Sep 3, 2026 | $15.89 | $16.29 | $15.46 | $15.86 | 2.26M |
| Sep 2, 2026 | $15.97 | $16.66 | $14.98 | $15.69 | 2.68M |
| Sep 1, 2026 | $15.39 | $16.0395 | $14.88 | $15.74 | 2.48M |
| Aug 31, 2026 | $15.46 | $15.79 | $15.175 | $15.27 | 2.93M |
| Aug 28, 2026 | $15.88 | $16.34 | $14.94 | $15.41 | 2.89M |
| Aug 27, 2026 | $16.95 | $17.05 | $15.50 | $16.12 | 5.43M |
| Aug 26, 2026 | $14.24 | $18.24 | $13.00 | $16.95 | 15.77M |
| Aug 25, 2026 | $13.96 | $14.86 | $13.92 | $14.38 | 3.44M |
| Aug 24, 2026 | $13.95 | $14.00 | $13.56 | $13.68 | 1.36M |
| Aug 21, 2026 | $13.60 | $14.33 | $13.53 | $13.85 | 2.09M |
| Aug 20, 2026 | $13.96 | $14.52 | $13.26 | $13.50 | 4.02M |
| Aug 19, 2026 | $13.94 | $14.44 | $13.76 | $14.14 | 1.96M |
| Aug 18, 2026 | $14.30 | $14.30 | $13.545 | $13.57 | 1.97M |
Latest BHVN news
The latest Smart Investors Daily articles mentioning BHVN.
Stock researchCompany · Overview
BHVN research
Overview
Company profile and research snapshot.
Company profile
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 10, 2026 | HC Wainwright & Co. | Neutral | — |
| Sep 8, 2026 | RBC Capital | Sector Perform | — |
| Aug 12, 2026 | Morgan Stanley | Overweight | — |
| Aug 11, 2026 | RBC Capital | Outperform | — |
| Jun 29, 2026 | B of A Securities | Underperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 10, 2026
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.
Yahoo · Sep 10, 2026
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
SeekingAlpha · Sep 10, 2026
Biohaven: The Hold Isn't The Problem (Rating Downgrade)
Biohaven faces challenges following a partial clinical hold on its lead asset, opakalim, and ongoing high cash burn. Read more on BHVN stock here.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
